Despite this disparity of views, a consensus is emerging that nNOS:NOS1AP interaction is a potential drug target for neurological and cardiovascular disorders (Li et al., 2013; Kapoor et al., 2014; Weber et al., 2014). This evidence concerns the gene NOS1AP and cardiovascular disorder.